HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study

PLoS MedicineBergqvist R, Ahlqvist VH, Lundberg M, et al. | October 19, 2021

Advertisement

Lipid-lowering HMG-CoA reductase inhibitors (statins) are reported to have pleiotropic effects on coagulation and immune mechanisms. Considering this, researchers herein examined the correlation of statin treatment with COVID-19 mortality.

  • Swedish health registers yielded data of a cohort of 963,876 residents of Stockholm, Sweden.

  • Follow-up of the cohort was done from March 1, 2020 until November 11, 2020.

  • Researchers matched prescription dispensation data to healthcare data and the Swedish Cause of Death Registry.

  • Multivariable cause-specific survival analysis was conducted to analyze the data.

  • After accounting for a series of preexisting health conditions and other factors, there appeared a moderately lower risk of COVID-19 mortality in correlation with receiving statin treatment.

  • Sensitivity analyses corroborated the association and no substantial variation in this association was recorded across risk groups.

Read the full article on PLoS Medicine

Advertisement